PipelineReview.com22h
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
BOSTON, MA, USA I 11, 2024 I Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...
PipelineReview.com23h
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway ...
PipelineReview.com23h
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
WILMINGTON, DE, USA I 11, 2024 I Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) ...
PipelineReview.com23h
Expression Therapeutics Announces Promising Phase 1 Results for Groundbreaking Hemophilia A Gene Therapy at ASH
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...
PipelineReview.com23h
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition
Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...
PipelineReview.com23h
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
SAN DIEGO, CA, USA I 11, 2024 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...
PipelineReview.com1d
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
COPENHAGEN, Denmark I 10, 2024 IZealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery ...
PipelineReview.com1d
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM, Sweden I 10, 2024 I Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...
PipelineReview.com1d
Huonslab Announces Enrollment and Administration of First Patient in Phase 1 Pivotal Study for Hydizyme™ (rHuPH20)
PANGYO, South Korea I 10, 2024 I Huonslab, a subsidiary of Huons Global (KOSDAQ: 084110), announced today the successful enrollment and ...
PipelineReview.com2d
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences ...
PipelineReview.com2d
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
GAITHERSBURG, MD, USA I 10, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ ...
PipelineReview.com2d
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...